Human Papillomavirus, Human Immunodeficiency Virus, and Oral Microbiota Interplay in Nigerian Youth (HOMINY): A Prospective Cohort Study Protocol by Jia Liu, Esosa Osagie, Paul Akhigbe, Nosakhare Idemudia, Ozoemene Obuekwe, Ruxton Adebiyi, Nicolas Schlecht, Yana Bromberg, Fidelis E Eki-Udoko, Nosayaba Osazuwa-Peters, Modupe Oluseun Coker

“…Blood samples are tested for HIV, Hepatitis B virus (HBV) and Hepatitis C virus (HCV), with CD4, CD8 and full blood counts performed. …”
Get full text

A prospective study to evaluate the clinical specificity of the cobas® MPX test kit for screening for HIV RNA, HCV RNA, and HBV DNA in blood donation samples using the cobas® 6800... by Lei Zhou, Lin Wang, Xiaofang Gong, Xiaochun Liu, Yaxuan Zou, Yingying Wang, Jinfeng Zeng, Liang Zang

“…Roche's advanced cobas® MPX assay detects human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) using the cobas® 6800/5800 Systems, based on real-time PCR technology, providing improved sensitivity. …”
Get full text

Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know by Emanuela De Bellis, Danilo Donnarumma, Adele Zarrella, Salvatore Maria Mazzeo, Annarita Pagano, Valentina Manzo, Ines Mazza, Francesco Sabbatino, Graziamaria Corbi, Pasquale Pagliano, Amelia Filippelli, Valeria Conti

“…Protease inhibitors, followed by nonnucleoside reverse transcriptase inhibitors and integrase inhibitors have been recognized as the main players in DDIs with antivirals used to control co-infection, such as Hepatitis C virus, or with drugs commonly used to treat HIV comorbidities, such as lipid-lowering agents, proton pump inhibitors and anticancer drugs. …”
Get full text

Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C by Manuela G. Neuman, Hemda Schmilovitz-Weiss, Nir Hilzenrat, Marc Bourliere, Patrick Marcellin, Cristhian Trepo, Tony Mazulli, George Moussa, Ankit Patel, Asad A. Baig, Lawrence Cohen

“…High levels of profibrinogenic cytokine transforming factor beta (TGF-β), metalloprotease (MMP2), and tissue inhibitor of matrix metalloprotease 1 (TIMP1) contribute to fibrogenesis in hepatitis C virus (HCV) infection and in alcohol-induced liver disease (ALD). …”
Get full text

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin by Hirokazu Suii, Itaru Ozeki, Ryoji Tatsumi, Masakatsu Yamaguchi, Mutsuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takumi Ohmura, Shuhei Hige, Yoshiyasu Karino, Joji Toyota

“…Interferon (IFN) and ribavirin (RBV) combination therapy was previously the standard of care for treatment of hepatitis C virus (HCV) genotype 2 infection. But, it often induced hemolytic anemia. …”
Get full text

Prioritization of potential pharmacological targets for the development of anti-hepatocarcinoma drugs modulating the extrinsic apoptosis pathway: the reconstruction and analysis... by P. S. Demenkov, E. A. Antropova, A. V. Adamovskaya, E. I. Mishchenko, T. M. Khlebodarova, T. V. Ivanisenko, N. V. Ivanisenko, A. S. Venzel, I. N. Lavrik, V. A. Ivanisenko

“…Aberrant gene methylation, along with hepatitis C virus (HCV) infection, are important risk factors for the development of hepatocellular carcinoma. …”
Get full text

MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase–signal transducer and activator of transcription pathway by Fanwei Liu, Bowen Liu, Shanshan Xu, Yinhua Ni, Xiaoli Liu

“…Significant overlap in the epidemiology and coinfection of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) has been identified, which accelerates the development of severe liver cirrhosis and hepatocellular carcinoma worldwide. …”
Get full text

Successful Endoscopic Injection Sclerotherapy of High-Risk Gastroesophageal Varices in a Cirrhotic Patient with Hemophilia A by Kohei Fukumoto, Hideyuki Konishi, Koichi Soga, Ki-ichiro Miyawaki, Hitoshi Okano, Masahito Minami, Naoki Wakabayashi, Shoji Mitsufuji, Norimasa Yoshida, Tomohisa Takagi, Nobuaki Yagi, Yuji Naito, Keisho Kataoka, Toshikazu Yoshikawa

“…A 68-year-old man with hemophilia A and liver cirrhosis caused by hepatitis C virus was referred to our hospital to receive prophylactic endoscopic treatment for gastroesophageal varices (GOV). …”
Get full text

Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study by Kim Hoffman, Gillian Leichtling, Sarah Shin, Andrew Seaman, Tonhi Gailey, Hunter C. Spencer, P. Todd Korthuis

“…Abstract Background The increase in opioid use disorder among young, nonurban people has fueled sharp rises in hepatitis C virus (HCV) infections. Innovative treatment models are needed that circumvent healthcare system barriers for people who use drugs (PWUD), particularly in rural areas. …”
Get full text

Endothelial Dysfunction Correlates with Liver Fibrosis in Chronic HCV Infection by Michele Barone, Maria Teresa Viggiani, Annabianca Amoruso, Serafina Schiraldi, Annapaola Zito, Fiorella Devito, Francesca Cortese, Michele Gesualdo, Natale Brunetti, Alfredo Di Leo, Pietro Scicchitano, Marco Matteo Ciccone

“…Background. Hepatitis C virus (HCV) infection can exert proatherogenic activities due to its direct action on vessel walls and/or via the chronic inflammatory process involving the liver. …”
Get full text

Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egy... by Giuseppe Indolfi, Diana M Gibb, Aya Mostafa, Sarah Pett, Yazdan Yazdanpanah, Sylvie Deuffic-Burban, Anthony E Ades, Karen Scott, Ali Judd, Nadia Hachicha-Maalej, Clotilde Lepers, Intira Jeannie Collins, Manal H El Sayed

“…Backgrounds and aims Pregnant women and children are not included in Egypt’s hepatitis C virus (HCV) elimination programmes. This study assesses the cost-effectiveness of several screening and treatment strategies for pregnant women and infants in Egypt.Design A Markov model was developed to simulate the cascade of care and HCV disease progression among pregnant women and their infants according to different screening and treatment strategies, which included: targeted versus universal antenatal screening; treatment of women in pregnancy or deferred till after breast feeding; treatment of infected children at 3 years vs 12 years. …”
Get full text

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure by Davide Scalabrini, Paolo Sciuto, Cristina Felicani, Antonia Rudilosso, Pietro Andreone

“…This article reports two different cases concerning respectively an 83-year-old female patient suffering from arterial hypertension, aneurysm of the sub-renal aorta, hepatitis C virus (HCV)-positive liver cirrhosis responsive to treatment with antiviral drugs, and a 2.0 cm diameter hepatocellular carcinoma (HCC) nodule localized in the hepatic segment III and a 53-year-old female patient with HCV-positive liver cirrhosis complicated by portal hypertension with splenomegaly, thrombocytopenia, and F3 esophageal varices at high risk of bleeding. …”
Get full text

Prospective evaluation of the impact of repeated whole prison testing for hepatitis C by Stuart McPherson, Naw April Phaw, Manoj Valappil, Carolyn Miller, Craig Thompson, Francesca McCullough, Caroline Allsop, Kate McQue, Ryan Jelley, Jenna Kerry, Jodi Aldridge, Tony Jefferson, Colin Lawton, Lee Christensen, Aung Min Thant

“…Introduction Chronic hepatitis C virus (HCV) infection is prevalent in prisons. …”
Get full text

Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients by Flaminia Ferri, Quirino Lai, Antonio Molinaro, Edoardo Poli, Lucia Parlati, Barbara Lattanzi, Gianluca Mennini, Fabio Melandro, Francesco Pugliese, Federica Maldarelli, Alessandro Corsi, Mara Riminucci, Manuela Merli, Massimo Rossi, Stefano Ginanni Corradini

“…No data are available on liver transplantation (LT) outcome and donor liver steatosis, classified as large droplet macrovesicular (Ld-MaS), small-droplet macrovesicular (Sd-MaS), and true microvesicular (MiS), taking into account the recipient Hepatitis C virus (HCV) status. Aim. We investigate the impact of allograft steatosis reclassified according to the Brunt classification on early graft function and survival after LT. …”
Get full text

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients by Carla De Benedittis, Mattia Bellan, Martina Crevola, Elena Boin, Matteo Nazzareno Barbaglia, Venkata Ramana Mallela, Paolo Ravanini, Elisa Ceriani, Stefano Fangazio, Pier Paolo Sainaghi, Michela Emma Burlone, Rosalba Minisini, Mario Pirisi

“…Our aim was to evaluate if the same holds true in chronic hepatitis C virus infection (HCV). With a case control retrospective study design, we selected 110 patients who developed HCC on a background of HCV infection, matching each patient for sex and age (±30 months) to three HCV-infected, non-HCC patients. …”
Get full text

Feasibility and Acceptability of Antenatal Hepatitis C Screening: A Pilot Study by Joseph Valamparampil, Jaswant Sira, Maxine Brown, Saket Singhal, Deirdre Kelly

“…Introduction. Hepatitis C virus (HCV) is not currently included in the United Kingdom routine antenatal screening program, but the latest guidelines from the Centers for Disease Control and Prevention, American Association for the Study of Liver Diseases, and Infectious Diseases Society of America recommend HCV screening for all pregnant women during each pregnancy. …”
Get full text

Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin by M. V. Mayevskaya, O. O. Znoyko, Ye. A. Klimova, S. L. Maximov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, Yu. N. Linkova

“…Study results prove high efficacy and safety of Algeron in suppression of hepatitis C virus replication and allow to recommend its application at previously untreated patients with CHC in a doze of 1,5 mkg/kg/wk for 24-48 wks in relation to genotype HCV.…”
Get full text

Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres) by M. V. Mayevskaya, M. S. Novruzbekov, I. M. Borovkov, D. G. Trofimova, M. S. Zharkova, V. D. Lunkov, K. N. Lutsyk, O. D. Olisov

“…An increase in the number of patients with autoimmune LC and LC associated with chronic hepatitis C virus (HCV) infection was observed. The conducted analysis of trends in the structure of HCC patients showed that chronic HCV and HBV infection is the main prerequisite for the development of cancer. …”
Get full text

Hepatitis B and C Viruses’ Infection and Associated Factors among Pregnant Women Attending Antenatal Care in Hospitals in the Amhara National Regional State, Ethiopia by Mulat Dagnew, Yihenew Million, Mucheye Gizachew, Setegn Eshetie, Gashaw Yitayew, Lakachew Asrade, Mulat Adefris, Feleke Moges, Moges Tiruneh

“…Serum samples were tested for hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody (anti-HCV) using ELISA. SPSS version 20 was used for data analysis, and a multivariable logistic regression analysis was used to assess the relationship between factors associated with hepatitis B virus and hepatitis virus C infection. …”
Get full text

Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: an 11-year retrospective cohort study in Gua... by Jun Yu, Hao Liang, Fengxiang Qin, Junjun Jiang, Chunwei Qin, Yunxuan Huang, Bingyu Liang, Yuexiang Xu, Jiegang Huang, Zhiliang Xu, Chuanyi Ning, Yanyan Liao, Ning Zang, Jingzhen Lai, Wudi Wei, Li Ye, Xionglin Qin

“…Objective To characterise the association between duration of exposure to antiretroviral treatment (ART) and liver damage in HIV patients with an initially normal baseline liver function and without hepatitis B virus (HBV)/hepatitis C virus (HCV) infection.Methods A retrospective cohort study was conducted in HIV-infected individuals with normal liver function parameters at ART initiation and without HBV/HCV infection, from 14 April 2004 to 13 April 2015 in Guigang city, Guangxi, China. …”
Get full text